Related references
Note: Only part of the references are listed.Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
Donald Hurley et al.
CLINICAL INFECTIOUS DISEASES (2021)
Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America
Arto A. Palmu et al.
VACCINE (2021)
A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States
David Fitz-Patrick et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
Patricia Richi et al.
VACCINES (2021)
Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis
Miguel Marques Antunes et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2021)
Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination
Youn H. Sheen et al.
JOURNAL OF ASTHMA (2020)
Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial
Wonyoung Choi et al.
CANCER RESEARCH AND TREATMENT (2020)
Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting
Hannah M. Garcia Garrido et al.
CLINICAL INFECTIOUS DISEASES (2020)
Pneumococcal vaccine coverage among individuals aged 18 to 64years old with underlying medical conditions in the UK: a retrospective database analysis
Ian Matthews et al.
BMC PUBLIC HEALTH (2020)
Serotype Distribution and Antimicrobial Susceptibility of Streptococcus pneumoniae in Pre- and Post-PCV7/13 Eras, Taiwan, 2002-2018
Chi-Jung Wu et al.
FRONTIERS IN MICROBIOLOGY (2020)
Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review
Yixue Shao et al.
EXPERT REVIEW OF VACCINES (2020)
Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
Hannah M. Garcia Garrido et al.
ECLINICALMEDICINE (2020)
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis
Nirma Khatri Vadlamudi et al.
VACCINE (2019)
Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia
Raul E. Isturiz et al.
VACCINE (2019)
Efficacy and accuracy of qSOFA and SOFA scores as prognostic tools for community-acquired and healthcare-associated pneumonia
Nobuhiro Asai et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study
Laura L. Hammitt et al.
VACCINE (2019)
Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases
Andrzej Ciszewski
VACCINE (2018)
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults >= 50 years of age
Susan J. Ermlich et al.
VACCINE (2018)
Response to pneumococcal vaccine in interstitial lung disease patients: Influence of systemic immunosuppressive treatment
Koji Kuronum et al.
VACCINE (2018)
Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis
Marielle van Aalst et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2018)
Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
Min-Joo Choi et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Clinical and economic burden of pneumococcal disease in US adults aged 19-64 years with chronic or immunocompromising diseases: an observational database study
Dongmu Zhang et al.
BMC INFECTIOUS DISEASES (2018)
Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Christopher Troeger et al.
LANCET INFECTIOUS DISEASES (2018)
Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010-2017
Kimiko Ubukata et al.
EMERGING INFECTIOUS DISEASES (2018)
Pneumococcal biliary tract infections - How rare are they?
Hiroshi Morioka et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)
M. T. T. Nguyen et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2017)
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians
S. Dirmesropian et al.
VACCINE (2017)
Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis
Evelyn Balsells et al.
PLOS ONE (2017)
Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Julia A. E. Walters et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Pneumococcal Vaccination Among Adults With Work-related Asthma
Katelynn E. Dodd et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2017)
Childhood Deaths Attributable to Invasive Pneumococcal Disease in England and Wales, 2006-2014
Godwin Oligbu et al.
CLINICAL INFECTIOUS DISEASES (2017)
Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis
Subhashis Mitra et al.
CLINICAL AND VACCINE IMMUNOLOGY (2016)
Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study
Olivier Brocq et al.
JOINT BONE SPINE (2016)
Optimizing seroprotection against pneumococcus in children with nephrotic syndrome using the 13-valent pneumococcal conjugate vaccine
Laure F. Pittet et al.
VACCINE (2016)
Status of research and development of pediatric vaccines for Streptococcus pneumoniae
Mark R. Alderson
VACCINE (2016)
Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France
Claire Janoir et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Cardiotoxicity during Invasive Pneumococcal Disease
Armand O. Brown et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
Mark van der Linden et al.
BMC INFECTIOUS DISEASES (2015)
Evaluation of antibody levels over 3 years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents
Taisuke Akamatsu et al.
CLINICAL BIOCHEMISTRY (2015)
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Pauline A. Waight et al.
LANCET INFECTIOUS DISEASES (2015)
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
Matthew R. Moore et al.
LANCET INFECTIOUS DISEASES (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency
Paul Loubet et al.
VACCINE (2015)
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults
Richard McFetridge et al.
VACCINE (2015)
Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
Shu-ling Hoshi et al.
PLOS ONE (2015)
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Lorry G. Rubin et al.
CLINICAL INFECTIOUS DISEASES (2014)
Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine
Rodrigo E. Mendes et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2014)
Epidemiology of Pediatric Pneumococcal Meningitis and Bacteremia in Latin America and the Caribbean A Systematic Review and Meta-analysis
Agustin Ciapponi et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2014)
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age
Richard N. Greenberg et al.
VACCINE (2014)
Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions
Kimberly M. Shea et al.
OPEN FORUM INFECTIOUS DISEASES (2014)
Inhaled Corticosteroids and the Risk of Pneumonia in People With Asthma A Case-Control Study
Tricia McKeever et al.
CHEST (2013)
How Effective is Vaccination in Preventing Pneumococcal Disease?
Daniel M. Musher
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2013)
Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147)
K. L. Slayter et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2013)
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
Lisa A. Jackson et al.
VACCINE (2013)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
Lisa A. Jackson et al.
VACCINE (2013)
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
Anneke Steens et al.
VACCINE (2013)
Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999 2011
Sandra S. Richter et al.
EMERGING INFECTIOUS DISEASES (2013)
Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells
Elizabeth A. Clutterbuck et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
S. van Assen et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Takotsubo (Stress) Cardiomyopathy
Scott W. Sharkey et al.
CIRCULATION (2011)
Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness
Laura L. Hammitt et al.
VACCINE (2011)
Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome
Christina D. Liakou et al.
VACCINE (2011)
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Inci Yildirim et al.
VACCINE (2010)
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Katherine L. O'Brien et al.
LANCET (2009)
Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease
Akitsugu Furumoto et al.
VACCINE (2008)
Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - A review
MJ Schultz et al.
CRITICAL CARE MEDICINE (2006)
Clinical efficacy of anti-pneumococcal vaccination in patients with COPD
I Alfageme et al.
THORAX (2006)
Asthma as a risk factor for invasive pneumococcal disease
TR Talbot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pneumococcal vaccination decreases atherosclerotic lesion formation:: molecular mimicry between Streptococcus pneumoniae and oxidized LDL
CJ Binder et al.
NATURE MEDICINE (2003)
Streptococcus pneumoniae-infected aneurysm extending from a persistent lobar pneumonia:: Case report and review of the literature
A Nijs et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2002)
Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae
AQ Khan et al.
INFECTION AND IMMUNITY (2002)
Atopic eczema is associated with delayed maturation of the antibody response to Pneumococcal vaccine
PD Arkwright et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Streptococcus pneumoniae endocarditis in adults - A multicenter study in France in the era of penicillin resistance (1991-1998)
A Lefort et al.
MEDICINE (2000)
Share Paper
